Across TCGA pan-cancer cohorts, TMEM129 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TMEM129 data layer compared with 23 for mass-spec protein and 1 for mutation status.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TMEM129 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM129 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.
HNSC and GBM are the cancer types where TMEM129 mass-spec protein most reproducibly stratifies survival.